164 related articles for article (PubMed ID: 7542572)
1. Complement inhibition by human vitronectin involves non-heparin binding domains.
Sheehan M; Morris CA; Pussell BA; Charlesworth JA
Clin Exp Immunol; 1995 Jul; 101(1):136-41. PubMed ID: 7542572
[TBL] [Abstract][Full Text] [Related]
2. Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9.
Milis L; Morris CA; Sheehan MC; Charlesworth JA; Pussell BA
Clin Exp Immunol; 1993 Apr; 92(1):114-9. PubMed ID: 7682159
[TBL] [Abstract][Full Text] [Related]
3. The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8, and C9 and perforin from cytolytic T-cells and inhibits their lytic activities.
Tschopp J; Masson D; Schäfer S; Peitsch M; Preissner KT
Biochemistry; 1988 May; 27(11):4103-9. PubMed ID: 2458130
[TBL] [Abstract][Full Text] [Related]
4. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9.
Tschopp J; Chonn A; Hertig S; French LE
J Immunol; 1993 Aug; 151(4):2159-65. PubMed ID: 8345200
[TBL] [Abstract][Full Text] [Related]
5. A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes by C5b-9.
Tomlinson S; Whitlow MB; Nussenzweig V
J Immunol; 1994 Feb; 152(4):1927-34. PubMed ID: 7509832
[TBL] [Abstract][Full Text] [Related]
6. Recombinant C345C and factor I modules of complement components C5 and C7 inhibit C7 incorporation into the complement membrane attack complex.
Thai CT; Ogata RT
J Immunol; 2005 May; 174(10):6227-32. PubMed ID: 15879120
[TBL] [Abstract][Full Text] [Related]
7. S-protein/vitronectin interaction with the C5b and the C8 of the complement membrane attack complex.
Su HR
Int Arch Allergy Immunol; 1996 Aug; 110(4):314-7. PubMed ID: 8768797
[TBL] [Abstract][Full Text] [Related]
8. Potent inhibition of terminal complement assembly by clusterin: characterization of its impact on C9 polymerization.
McDonald JF; Nelsestuen GL
Biochemistry; 1997 Jun; 36(24):7464-73. PubMed ID: 9200695
[TBL] [Abstract][Full Text] [Related]
9. H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement.
Whitlow MB; Iida K; Stefanova I; Bernard A; Nussenzweig V
Cell Immunol; 1990 Mar; 126(1):176-84. PubMed ID: 1689219
[TBL] [Abstract][Full Text] [Related]
10. Formation of the terminal complement complex on agarose beads: further evidence that vitronectin (complement S-protein) inhibits C9 polymerization.
Johnson E; Berge V; Høgåsen K
Scand J Immunol; 1994 Mar; 39(3):281-5. PubMed ID: 7510414
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the lytic action of cell-bound terminal complement components by human high density lipoproteins and apoproteins.
Rosenfeld SI; Packman CH; Leddy JP
J Clin Invest; 1983 Apr; 71(4):795-808. PubMed ID: 6403580
[TBL] [Abstract][Full Text] [Related]
12. Molecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b-8 assembly.
Podack ER; Tschoop J; Müller-Eberhard HJ
J Exp Med; 1982 Jul; 156(1):268-82. PubMed ID: 6177822
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of C9 polymerization within the SC5b-9 complex of complement by S-protein.
Podack ER; Preissner KT; Müller-Eberhard HJ
Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():89-96. PubMed ID: 6587746
[TBL] [Abstract][Full Text] [Related]
14. Role of a disulfide-bonded peptide loop within human complement C9 in the species-selectivity of complement inhibitor CD59.
Husler T; Lockert DH; Sims PJ
Biochemistry; 1996 Mar; 35(10):3263-9. PubMed ID: 8605162
[TBL] [Abstract][Full Text] [Related]
15. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
Rollins SA; Sims PJ
J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
[TBL] [Abstract][Full Text] [Related]
16. Complement component C7 is a plasminogen-binding protein.
Reinartz J; Hänsch GM; Kramer MD
J Immunol; 1995 Jan; 154(2):844-50. PubMed ID: 7814888
[TBL] [Abstract][Full Text] [Related]
17. Evidence of direct insertion of terminal complement proteins into cell membrane bilayers during cytolysis. Labeling by a photosensitive membrane probe reveals a major role for the eighth and ninth components.
Steckel EW; Welbaum BE; Sodetz JM
J Biol Chem; 1983 Apr; 258(7):4318-24. PubMed ID: 6833260
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.
Rollins SA; Zhao J; Ninomiya H; Sims PJ
J Immunol; 1991 Apr; 146(7):2345-51. PubMed ID: 1706395
[TBL] [Abstract][Full Text] [Related]
19. Transmembrane channel-formation by five complement proteins.
Müller-Eberhard HJ
Biochem Soc Symp; 1985; 50():235-46. PubMed ID: 2428370
[TBL] [Abstract][Full Text] [Related]
20. Calcium-loaded erythrocytes have a defect in complement regulation distinct from that resulting from exposure to 2-aminoethylisothiouronium bromide.
Test ST; Mitsuyoshi J
Blood; 1995 Oct; 86(7):2799-806. PubMed ID: 7545473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
